Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL Study
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Leber hereditary optic neuropathy (LHON) is a maternally inherited mitochondrial disease whose primary clinical manifestation is bilateral visual loss. Only a single therapy, idebenone, is approved in Europe for use in exceptional circumstances and no therapy is currently approved in the USA. LHON remains a disease with a high unmet medical need. This is a report of an open-label, single-center, dose-escalation study that evaluated the safety and tolerability of lenadogene nolparvovec in 15 subjects with LHON for up to 5 years following a single intravitreal injection at four dose levels. Subjects were enrolled sequentially in four cohorts followed by an additional cohort at the dose selected, and safety was assessed by an independent data safety monitoring board (DSMB) prior to any dose escalation. Overall, the treatment was well tolerated during the 5-year follow-up. No serious adverse events were considered related to treatment, no unexpected adverse events occurred, and no grade 3 or 4 Common Terminology Criteria for Adverse Events were reported. Anterior chamber inflammation and vitritis were mostly managed with topical steroids, and ocular inflammation was considered to be dose limiting by the DSMB based on the benefits/risks for the subjects. Analysis of the logarithm of the minimal angle of resolution (LogMAR) visual acuity in both treated and untreated eyes showed clinically relevant and durable improvements compared with baseline. Mean improvements of − 0.44 and − 0.49 LogMAR for treated and untreated eyes, respectively, were noted, with a mean (± standard deviation) final value of LogMAR + 1.96 ± 0.60 and + 1.65 ± 0.34, respectively, at 5 years post-treatment administration. For the six subjects treated with the optimal dose level (9 × 10 10 viral genomes [vg]/eye), the mean visual acuity improvement from baseline reached − 0.68 LogMAR for treated eyes and − 0.64 LogMAR for untreated eyes, with a mean final value of LogMAR + 1.77 ± 0.52 and + 1.78 ± 0.34, respectively. While there was a meaningful improvement in visual acuity for REVEAL subjects, the final visual acuity was less favorable than that seen in the two subsequent pivotal phase III studies in which subjects were treated earlier during the course of their disease. Lenadogene nolparvovec was well tolerated with a good safety profile during 5 years of follow-up and may offer meaningful lasting improvements in vision for this LHON population. EUDRACT N° 2013-001405-90.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The dose of lenadogene nolparvovec selected in REFLECT (9 × 1010 vg/eye) was the maximal tolerated dose determined in the previous phase 1/2a REVEAL study.15,21”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“It is also the first clinical study assessing the efficacy of a bilateral IVT of lenadogene nolparvovec, while in the three previous clinical studies REVEAL,21 REVERSE16–18 and RESCUE,17–19 lenadogene nolparvovec was exclusively administered as unilateral IVT.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.03.057 · Cited by 4,396
Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy
Wallace, D. C., Singh, G., Lott, M. T., Hodge, J. A., Schurr, T. G., Lezza, A. M. S., Elsas, L. J., & Nikoskelainen, E. K. (1988) · Science · doi:10.1126/science.3201231 · Cited by 2,440 · cited 2×
“LHON was the first inherited human disease associated with point mutations in the mitochondrial DNA (mtDNA) [2] and is considered the most common inherited genetic mitochondrial disorder [3].”
BackgroundISCEV Standard for full-field clinical electroretinography (2015 update)
McCulloch, D. L., Marmor, M. F., Brigell, M. G., Hamilton, R., Holder, G. E., Tzekov, R., & Bach, M. (2015) · Documenta Ophthalmologica · doi:10.1007/s10633-014-9473-7 · Cited by 1,313
ISCEV Standard for full-field clinical electroretinography (2008 update)
Marmor, M. F., Fulton, A. B., Holder, G. E., Miyake, Y., Brigell, M., Bach, M., & (for the International Society for Clinical Electrophysiology of Vision) (2009) · Documenta Ophthalmologica · doi:10.1007/s10633-008-9155-4 · Cited by 1,003
Zingg, B., Chou, X.-L., Zhang, Z.-G., Mesik, L., Liang, F., Tao, H. W., & Zhang, L. I. (2017) · Neuron · doi:10.1016/j.neuron.2016.11.045 · Cited by 752
Standardizatlon of Vitreal inflammatory Activity in Intermediate and Posterior Uveitis
Nussenblatt, R. B., Palestine, A. G., Chan, C.-C., & Roberge, F. (1985) · Ophthalmology · doi:10.1016/s0161-6420(85)34001-0 · Cited by 684 · cited 1×
“Anterior chamber inflammation and vitritis were mostly assessed as mild in severity, with anterior chamber cell grade of 1 + or lower (according to Standardization of Uveitis Nomenclature Working Group criteria; scores range from 0 to 4 + , with lower scores indicating less cells visible in the anterior chamber and lo…”
BackgroundA randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy.
Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., et al. (2011) · Brain · doi:10.1093/brain/awr170 · Cited by 578 · cited 3×
“Therapeutic options for adolescent and adult patients with LHON are currently limited to idebenone, and its benefits in patients with ND4 LHON are limited [19, 20].”
BackgroundInfluentialLeber hereditary optic neuropathy
Man, P. Y. W., Turnbull, D. M., & Chinnery, P. F. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.3.162 · Cited by 520 · cited 1×
“It is estimated that approximately 50% of males and 10% of females who carry one of the primary point mutations will manifest the clinical disease [6].”
BackgroundRiordan-Eva, P., Sanders, M. D., Govan, G. G., Sweeney, M. G., Costa, J. D., & Harding, A. E. (1995) · Brain · doi:10.1093/brain/118.2.319 · Cited by 490
The Epidemiology of Leber Hereditary Optic Neuropathy in the North East of England
Man, P. Y. W., Griffiths, P. G., Brown, D. T., Howell, N., Turnbull, D. M., & Chinnery, P. F. (2003) · The American Journal of Human Genetics · doi:10.1086/346066 · Cited by 483 · cited 1×
“LHON was the first inherited human disease associated with point mutations in the mitochondrial DNA (mtDNA) [2] and is considered the most common inherited genetic mitochondrial disorder [3].”
Background
Cited by
Newman, N. J., Yu-Wai-Man, P., Biousse, V., & Carelli, V. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00174-0 · Cited by 97
Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy
Newman, N. J., Yu-Wai-Man, P., Subramanian, P. S., Moster, M. L., Wang, A.-G., Donahue, S. P., Leroy, B. P., Carelli, V., Biousse, V., Vignal-Clermont, C., et al. (2023) · Brain · doi:10.1093/brain/awac421 · Cited by 87
“The dose of lenadogene nolparvovec selected in REFLECT (9 × 10(10) vg/eye) was the maximal tolerated dose determined in the previous phase 1/2a REVEAL study.(15,21) This dose was also selected in the phase 3 studies RESCUE and REVERSE.”
Self-citationBiousse, V., Newman, N. J., Yu-Wai-Man, P., Carelli, V., Moster, M. L., Vignal-Clermont, C., Klopstock, T., Sadun, A. A., Sergott, R. C., Hage, R., et al. (2021) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001367 · Cited by 78
“Administered as a unilateral intravitreal injection to MT-ND4 patients, lenadogene nolparvovec showed a good safety profile in a phase 1/2 clinical trial including 5 years of followup after treatment administration (9).”
MethodSelf-citationNewman, N. J., Yu-Wai-Man, P., Carelli, V., Biousse, V., Moster, M. L., Vignal-Clermont, C., Sergott, R. C., Klopstock, T., Sadun, A. A., Girmens, J.-F., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.662838 · Cited by 64
Self-citationDevelopments in the Treatment of Leber Hereditary Optic Neuropathy
Chen, B. S., Yu‐Wai‐Man, P., & Newman, N. J. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01246-y · Cited by 44
Metadata
- Authors
- Vignal-Clermont, C., Girmens, J.-F., Audo, I., Said, S. M., Errera, M.-H., Plaine, L., O’Shaughnessy, D., Taiel, M., & Sahel, J.-A.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- GenSight Biologics (France) (FR)
- Corresponding author
- Taiel, Magali
- Venue
- BioDrugs
- Published
- 2021-02-10
- Volume
- 35
- Issue
- 2
- Pages
- 201-214
- ISSN
- 1172-7039 (ISSN-L)
- 1173-8804
- 1179-190X
- PMC
- PMC7952288
- OpenAlex
- W3128161654
- Cited by
- 51
- References
- 42
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 4 · 2023: 9 · 2022: 13 · 2021: 4
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- BioDrugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- GenSight Biologics
- Topics
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- Leber's hereditary optic neuropathy, intravitreal gene therapy, mitochondrial disease, visual acuity, safety and tolerability, ocular inflammation, dose escalation, idebenone, blindness prevention, long-term follow-up, ocular adverse effects
- MeSH terms
- Europe, Humans, Mutation, Visual Fields, Genetic Therapy, Optic Atrophy, Hereditary, Leber, Tomography, Optical Coherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL Study. https://app.cochat.ai/papers/10.1007/s40259-021-00468-9
- The paper
- Vignal-Clermont, C., Girmens, J.-F., Audo, I., Said, S. M., Errera, M.-H., Plaine, L., O’Shaughnessy, D., Taiel, M., & Sahel, J.-A. (2021). Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL Study. BioDrugs. https://doi.org/10.1007/s40259-021-00468-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.